| pubmed-article:10052604 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10052604 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:10052604 | lifeskim:mentions | umls-concept:C0687725 | lld:lifeskim |
| pubmed-article:10052604 | lifeskim:mentions | umls-concept:C0031676 | lld:lifeskim |
| pubmed-article:10052604 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:10052604 | lifeskim:mentions | umls-concept:C0348035 | lld:lifeskim |
| pubmed-article:10052604 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:10052604 | pubmed:dateCreated | 1999-5-3 | lld:pubmed |
| pubmed-article:10052604 | pubmed:abstractText | Antiphospholipid antibodies (APA) are a generic term describing antibodies that recognize various phospholipids. Hepatocyte damage is a cardinal event in the course of alcoholic liver injury and autoantibodies against phospholipids could play an important role in this process. APA in alcoholic patients seem to reflect membrane lesions, impairment of immunological reactivity, liver disease progression and they correlate significantly with disease severity. LDL oxidation is supposed to be one of the most important pathogenic mechanisms of atherosclerosis and antibodies against oxidized low-density lipoprotein (oxLDL) are some kind of an epiphenomenon of this process. The scope of our study was to determine some autoantibodies (IgG-oxLDL and antiphospholipid antibodies) and their possible changes in alcoholic patients. We studied IgG-oxLDL and four APA - anticardiolipin antibodies (ACA), antiphosphatidylserine antibodies (APSA) antiphosphatidylethanolamine antibodies (APE) and antiphosphatidylcholine antibodies (APCA) in 35 alcoholic patients with mildly affected liver function at the beginning of the abuse treatment. The control group consisted of 60 healthy blood donors. In the studied group, we obtained positive results concerning total ACA in 17.1 % of alcoholic patients (8.3 % in the control group), 11.4 % IgG-ACA (6.7 %), 8.6 % IgM-ACA (3.3 %), 14.3 % total APE (6.7 %), 14.3 % total APCA (8.3 %) and 20 % total APSA (8.3 % in the control group). The IgG-oxLDL (406.4+/-52.5 vs 499.9+/-52.5 mU/ml) was not affected in alcoholic patients. We conclude that the autoantibodies against oxLDL are present in sera of alcoholics and healthy blood donors. Based on our results which revealed a wide range of IgG-oxLDL titres in the healthy population, this parameter does not appear to be very promising for the evaluation of the risk of atherosclerosis. Alcoholics with only mild affection of liver functions did not exhibit a significantly higher prevalence of all studied antiphospholipid antibodies (ACA, APSA, APE, APCA) which could lead to membrane lesions in these patients. | lld:pubmed |
| pubmed-article:10052604 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10052604 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10052604 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10052604 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10052604 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10052604 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10052604 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10052604 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10052604 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10052604 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10052604 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10052604 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10052604 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10052604 | pubmed:issn | 0862-8408 | lld:pubmed |
| pubmed-article:10052604 | pubmed:author | pubmed-author:PopovPP | lld:pubmed |
| pubmed-article:10052604 | pubmed:author | pubmed-author:NesporKK | lld:pubmed |
| pubmed-article:10052604 | pubmed:author | pubmed-author:MikulíkováLL | lld:pubmed |
| pubmed-article:10052604 | pubmed:author | pubmed-author:FialováLL | lld:pubmed |
| pubmed-article:10052604 | pubmed:author | pubmed-author:ZimaTT | lld:pubmed |
| pubmed-article:10052604 | pubmed:author | pubmed-author:MalbohanI MIM | lld:pubmed |
| pubmed-article:10052604 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10052604 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:10052604 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10052604 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10052604 | pubmed:pagination | 351-5 | lld:pubmed |
| pubmed-article:10052604 | pubmed:dateRevised | 2008-4-2 | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:meshHeading | pubmed-meshheading:10052604... | lld:pubmed |
| pubmed-article:10052604 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:10052604 | pubmed:articleTitle | Antibodies against phospholipids and oxidized LDL in alcoholic patients. | lld:pubmed |
| pubmed-article:10052604 | pubmed:affiliation | First Institute of Medical Chemistry and Biochemistry, First Faculty of Medicine, Charles University, Prague, Czech Republic. | lld:pubmed |
| pubmed-article:10052604 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10052604 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10052604 | lld:pubmed |
